Intra-articular Lidocaine
PreclinicalSmall molecule
Intra-articular Lidocaine is one of 8 small molecule programs targeting Knee Injury. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Knee Injury
#DrugCompanyPhaseTrials
1Naropin
FFresenius Kabi Oncology Ltd.
Approved
Decadron
AAspen Global Incorporated
Approved
Fondaparinux Sodium
GSKPhase 3
Nadroparin
GSKPhase 3
Zometa
PfizerPhase 1
Kineret
SSwedish Orphan Biovitrum
Phase 1
MS Contin
Merck & Co.Preclinical
Intra-articular Lidocaine
KKendall Healthcare Group, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Knee Injury1 trial
Quadriceps Motor Unit Adaptation to Simulated Knee Injury
Not yet recruiting·—·N/A·NCT06999057·45 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intra-articular Lidocaine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKendall Healthcare Group, Ltd.